Le Lézard
Classified in: Health, Science and technology, Business
Subjects: CALENDAR OF EVENTS, SHAREHOLDER RIGHTS PLANS

XORTX Announces Date for Rescheduled Special Meeting of Shareholders


CALGARY, Alberta, Oct. 25, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its earlier press release, the special meeting of shareholders has been rescheduled to 10:00 a.m. (Calgary time) on Friday, October 27, 2023 (the "Meeting").

At the Meeting shareholders will consider a consolidation of the Company's issued and outstanding shares in order for the Company to regain compliance with the continued listing requirements for the NASDAQ Capital Market.

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with two clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Respiratory Viral infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients with kidney disease. Additional information on XORTX is available at www.xortx.com.

For more information, please contact:

Allen Davidoff, CEO
[email protected] or +1 403 455 7727

Media Inquiries, OIipriya Das, PhD, MSc
[email protected] or +1 409 365 3641

Nick Rigopulos, Director of Communications
[email protected] or +1 617 901 0785
  

Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Forward-Looking Statements

This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX are contained under the heading "Risk Factors" in XORTX's Annual Information Form filed with the applicable Canadian securities regulators and the Company's 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.



These press releases may also interest you

at 09:35
As businesses grapple with evolving customer expectations and the rapid advancement of AI, the need for customer service solutions that are both intelligent and deeply human has never been greater. In recognition of this shift, Gladly has been named...

at 09:31
Our Kids Read (OKR), a nonprofit organization dedicated to promoting literacy among underserved children, will celebrate the grand opening of the nation's first Free Diverse Children's Bookstore on Saturday, Feb. 15th, at 2025 10am-2pm Eastpoint Mall...

at 09:30
IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that the Hong Kong Department of Health (DOH) has...

at 09:05
Omeros Corporation today announced the availability on its website of materials accompanying two presentations given at the 2025 Tandem Meetings ? the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and...

at 09:05
Zuora, Inc., a leading monetization platform for modern business, today announced the completion of its acquisition by Silver Lake, the global leader in technology investing, in partnership with an affiliate of GIC Pte. Ltd. ("GIC"), for $10.00 per...

at 09:05
Weave , a leading all-in-one customer experience and payments software platform for small and medium-sized healthcare businesses, today announced an integration with Practice Fusion, a leading cloud-based Electronic Health Records (EHR) software for...



News published on and distributed by: